Table of Contents Author Guidelines Submit a Manuscript
Journal of Chemistry
Volume 2015, Article ID 162956, 11 pages
http://dx.doi.org/10.1155/2015/162956
Research Article

Towards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic Agents In Vitro

1Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Łódź, 90-236 Łódź, Poland
2Department of Experimental Hematology, Medical University of Łódź, 93-510 Łódź, Poland
3Department of Hematology, Medical University of Łódź, 93-510 Łódź, Poland

Received 4 December 2014; Revised 5 March 2015; Accepted 5 March 2015

Academic Editor: Philippe Jeandet

Copyright © 2015 Jolanta D. Żołnierczyk et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Gaidano, R. Foà, and R. Dalla-Favera, “Molecular pathogenesis of chronic lymphocytic leukemia,” The Journal of Clinical Investigation, vol. 122, no. 10, pp. 3432–3438, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Smolewski, M. Witkowska, and A. Korycka-Wołowiec, “New insights into biology, prognostic factors, and current therapeutic strategies in chronic lymphocytic leukemia,” ISRN Oncology, vol. 2013, Article ID 740615, 7 pages, 2013. View at Publisher · View at Google Scholar
  3. M. Wu, A. Akinleye, and X. Zhu, “Novel agents for chronic lymphocytic leukemia,” Journal of Hematology and Oncology, vol. 6, no. 1, article 36, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Cuneo, F. Cavazzini, M. Ciccone et al., “Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups,” Cancer Medicine, vol. 3, no. 3, pp. 555–564, 2014. View at Publisher · View at Google Scholar
  5. L. Amrein, M. Shawi, J. Grenier, R. Aloyz, and L. Panasci, “The phosphatidylinositol-3 kinase i inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro,” International Journal of Cancer, vol. 133, no. 1, pp. 247–252, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. J. C. Gea-Banacloche, “Rituximab-associated infections,” Seminars in Hematology, vol. 47, no. 2, pp. 187–198, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. A. R. Tonelli, R. Lottenberg, R. W. Allan, and P. S. Sriram, “Rituximab-induced hypersensitivity pneumonitis,” Respiration, vol. 78, no. 2, pp. 225–229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. M. L. Hartman and Z. M. Kilianska, “Lipoprotein lipase: a new prognostic factor in chronic lymphocytic leukaemia,” Contemporary Oncology, vol. 16, no. 6, pp. 474–479, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. D. E. Spaner, E. Lee, Y. Shi et al., “PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia,” Leukemia, vol. 27, no. 5, pp. 1090–1099, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. M. F. Mulas, C. Abete, D. Pulisci et al., “Cholesterol esters as growth regulators of lymphocytic leukaemia cells,” Cell Proliferation, vol. 44, no. 4, pp. 360–371, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. T. P. Ahern, T. L. Lash, P. Damkier, P. M. Christiansen, and D. P. Cronin-Fenton, “Statins and breast cancer prognosis: evidence and opportunities,” The Lancet Oncology, vol. 15, no. 10, pp. e461–e468, 2014. View at Publisher · View at Google Scholar
  12. P. Jiang, R. Mukthavaram, Y. Chao et al., “In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells,” British Journal of Cancer, vol. 111, no. 8, pp. 1562–1571, 2014. View at Publisher · View at Google Scholar
  13. A. Sławińska-Brych, B. Zdzisińska, and M. Kandefer-Szerszeń, “Fluvastatin inhibits growth and alters the malignant phenotype of the C6 glioma cell line,” Pharmacological Reports, vol. 66, no. 1, pp. 121–129, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. W. A. Maltese and J. R. Aprille, “Relation of mevalonate synthesis to mitochondrial ubiquinone content and respiratory function in cultured neuroblastoma cells,” The Journal of Biological Chemistry, vol. 260, no. 21, pp. 11524–11529, 1985. View at Google Scholar · View at Scopus
  15. I.-M. Astrand, E. Fries, T. Chojnacki, and G. Dallner, “Inhibition of dolichyl phosphate biosynthesis by compactin in cultured rat hepatocytes,” European Journal of Biochemistry, vol. 155, no. 2, pp. 447–452, 1986. View at Publisher · View at Google Scholar · View at Scopus
  16. A. W. Alberts, “Lovastatin and simvastatin—inhibitors of HMG CoA reductase and cholesterol biosynthesis,” Cardiology, vol. 77, no. 4, pp. 14–21, 1990. View at Google Scholar · View at Scopus
  17. N. Vallianou, A. Kostantinou, M. Kougias, and C. Kazazis, “Statins and Cancer,” Anti-Cancer Agents in Medicinal Chemistry, vol. 14, no. 5, pp. 706–712, 2014. View at Publisher · View at Google Scholar
  18. J. H. Jackson, C. G. Cochrane, J. R. Bourne, P. A. Solski, J. E. Buss, and C. J. Der, “Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 8, pp. 3042–3046, 1990. View at Publisher · View at Google Scholar · View at Scopus
  19. A. A. Al-Haidari, I. Syk, and H. Thorlacius, “HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation,” Biochemical and Biophysical Research Communications, vol. 446, no. 1, pp. 68–72, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Ishikawa, H. Hayashi, K. Kinoshita et al., “Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer,” International Journal of Cancer, vol. 135, no. 11, pp. 2528–2536, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Podhorecka, D. Halicka, P. Klimek, M. Kowal, S. Chocholska, and A. Dmoszynska, “Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells,” Annals of Hematology, vol. 89, no. 11, pp. 1115–1124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. J. D. Zołnierczyk, A. Borowiak, P. Hikisz et al., “Promising anti-leukemic activity of atorvastatin,” Oncology Reports, vol. 29, no. 5, pp. 2065–2071, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. B. D. Cheson, J. M. Bennett, M. Grever et al., “National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment,” Blood, vol. 87, no. 12, pp. 4990–4997, 1996. View at Google Scholar · View at Scopus
  24. A. Kobylińska, J. Bednarek, J. Z. Blonski et al., “In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and/or mitoxantrone,” Oncology Reports, vol. 16, no. 6, pp. 1389–1395, 2006. View at Google Scholar · View at Scopus
  25. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the Folin phenol reagent,” The Journal of Biological Chemistry, vol. 193, no. 1, pp. 265–275, 1951. View at Google Scholar · View at Scopus
  26. U. K. Laemmli, “Cleavage of structural proteins during the assembly of the head of bacteriophage T4,” Nature, vol. 227, no. 5259, pp. 680–685, 1970. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Towbin, T. Staehelin, and J. Gordon, “Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications,” Proceedings of the National Academy of Sciences of the United States of America, vol. 76, no. 9, pp. 4350–4354, 1979. View at Publisher · View at Google Scholar · View at Scopus
  28. D. J. McConkey, “Calcium-dependent, interleukin 1-converting enzyme inhibitor-insensitive degradation of lamin B1 and DNA fragmentation in isolated thymocyte nuclei,” The Journal of Biological Chemistry, vol. 271, no. 37, pp. 22398–22406, 1996. View at Google Scholar
  29. P. Garnier, W. Ying, and R. A. Swanson, “Ischemic preconditioning by caspase cleavage of poly(ADP-ribose) polymerase-1,” Journal of Neuroscience, vol. 23, no. 22, pp. 7967–7973, 2003. View at Google Scholar · View at Scopus
  30. P. Cafforio, F. Dammacco, A. Gernone, and F. Silvestris, “Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells,” Carcinogenesis, vol. 26, no. 5, pp. 883–891, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. I. Yavasoglu, G. Sargin, G. Kadikoylu, A. Karul, and Z. Bolaman, “The activity of atorvastatin and rosiglitazone on CD38, ZAP70 and apoptosis in lymphocytes of B-cell chronic lymphocytic leukemia in vitro,” Medical Oncology, vol. 30, no. 3, article 603, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Al-harbi, B. T. Hill, S. Mazumder et al., “An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737,” Blood, vol. 118, no. 13, pp. 3579–3590, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Furlan, F. Villanova, F. Pietrogrande, M. Celadin, M. Sanzari, and F. Vianello, “Low-dose fludarabine increases rituximab cytotoxicity in B-CLL cells by triggering caspases activation in vitro,” Leukemia & Lymphoma, vol. 51, no. 1, pp. 107–113, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. A. G. Bosanquet and P. B. Bell, “Enhanced ex vivo drug sensitivity testing of chronic lymphocytic leukaemia using refined disc assay methodology,” Leukemia Research, vol. 20, no. 2, pp. 143–153, 1996. View at Publisher · View at Google Scholar · View at Scopus
  35. A. G. Bosanquet, S. M. Richards, R. Wade et al., “Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing,” British Journal of Haematology, vol. 146, no. 4, pp. 384–395, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. J. D. Żołnierczyk, A. Borowiak, J. Z. Blonski et al., “In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent,” Pharmacological Reports, vol. 65, no. 2, pp. 460–475, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. X.-J. Yan, E. Albesiano, N. Zanesi et al., “B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 31, pp. 11713–11718, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. U. Klein and R. Dalla-Favera, “New insights into the pathogenesis of chronic lymphocytic leukemia,” Seminars in Cancer Biology, vol. 20, no. 6, pp. 377–383, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Bagnara, M. S. Kaufman, C. Calissano et al., “A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease,” Blood, vol. 117, no. 20, pp. 5463–5472, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. A. A. Filip, B. Ciseł, and E. Wąsik-Szczepanek, “Guilty bystanders: nurse-like cells as a model of microenvironmental support for leukemic lymphocytes,” Clinical and Experimental Medicine, vol. 15, no. 1, pp. 73–83, 2015. View at Publisher · View at Google Scholar
  41. E. Matutes, A. G. Bosanquet, R. Wade, S. M. Richards, M. Else, and D. Catovsky, “The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry,” Leukemia, vol. 27, no. 2, pp. 507–510, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Robak and P. Robak, “Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias,” Current Pharmaceutical Design, vol. 18, no. 23, pp. 3373–3388, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. E. Rosati, R. Sabatini, G. Rampino et al., “Novel targets for endoplasmic reticulum stress-induced apoptosis in B-CLL,” Blood, vol. 116, no. 15, pp. 2713–2723, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. X. Peng, W. Li, L. Yuan, R. G. Mehta, L. Kopelovich, and D. L. McCormick, “Inhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR-182 and p21,” PLoS ONE, vol. 8, no. 8, Article ID e70442, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Ghavami, P. Sharma, B. Yeganeh et al., “Airway mesenchymal cell death by mevalonate cascade inhibition: integration of autophagy, unfolded protein response and apoptosis focusing on Bcl2 family proteins,” Biochimica et Biophysica Acta, vol. 1843, no. 7, pp. 1259–1271, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. E. Głodkowska-Mrowka, P. Mrowka, G. W. Basak et al., “Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib,” Experimental Hematology, vol. 42, no. 6, pp. 439–447, 2014. View at Publisher · View at Google Scholar
  47. M. Winiarska, J. Bil, E. Wilczek et al., “Statins impair antitumor effects of Rituximab by inducing conformational changes of CD20,” PLoS Medicine, vol. 5, no. 3, article e64, 2008. View at Publisher · View at Google Scholar
  48. A. Poggi, S. Boero, A. Musso, and M. R. Zocchi, “Selective role of mevalonate pathway in regulating perforin but not FasL and TNFalpha release in human natural killer cells,” PLoS ONE, vol. 8, no. 5, Article ID e62932, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Novak, B. Binnington, B. Ngan, K. Chadwick, N. Fleshner, and C. A. Lingwood, “Cholesterol masks membrane glycosphingolipid tumor-associated antigens to reduce their immunodetection in human cancer biopsies,” Glycobiology, vol. 23, no. 11, pp. 1230–1239, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Pisanti, P. Picardi, E. Ciaglia, A. D’Alessandro, and M. Bifulco, “Novel prospects of statins as therapeutic agents in cancer,” Pharmacological Research, vol. 88, pp. 84–98, 2014. View at Publisher · View at Google Scholar
  51. Y. K. Chae, L. Trinh, P. Jain et al., “Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia.,” Blood, vol. 123, no. 9, pp. 1424–1426, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. S. J. Lee, I. Lee, J. Lee, C. Park, and W. K. Kang, “Statins potentiate the anti-angiogenic effects of bevacizumab in human colorectal cancer,” The British Journal of Cancer, vol. 111, no. 3, pp. 497–505, 2014. View at Google Scholar
  53. S. Bonovas, “Statins: do they have a potential role in cancer prevention and modifying cancer-related outcomes?” Drugs, vol. 74, no. 16, pp. 1841–1848, 2014. View at Publisher · View at Google Scholar
  54. M. F. Carrascosa, J. R. Salcines-Caviedes, M. I. Lucena, and R. J. Andrade, “Acute liver failure following atorvastatin dose escalation: is there a threshold dose for idiosyncratic hepatotoxicity?” Journal of Hepatology, vol. 62, no. 3, pp. 751–752, 2015. View at Publisher · View at Google Scholar
  55. U. K. Sampson, M. F. Linton, and S. Fazio, “Are statins diabetogenic?” Current Opinion in Cardiology, vol. 26, no. 4, pp. 342–347, 2011. View at Publisher · View at Google Scholar · View at Scopus